MDSpire - Summary
From the Journals

Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence

“Adjuvant pembrolizumab plus belzutifan demonstrated a statistically significant and clinically meaningful improvement in disease-free survival vs pembrolizumab plus placebo in patients with clear cel...

Share

The phase III LITESPARK-022 study investigated the combination of adjuvant pembrolizumab and belzutifan in patients with clear cell renal cell carcinoma at increased risk of recurrence post-nephrectomy. Results showed a statistically significant improvement in disease-free survival compared to pembrolizumab with placebo, with an estimated 24-month rate of 80.7% for the combination therapy versus 73.7% for pembrolizumab alone. While the safety profile was consistent with each drug, further long-term studies are required to assess overall survival benefits.

Original Source(s)

Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence

  • by Jo Cavallo

  • March 31, 2026

Related Content

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsore...

Advancing Precision Oncology: What Pooled Trial Data Reveal About 177 Lu-PSMA-617 in mCRPC

Radiopharmaceutical therapy is rapidly reshaping the treatment landscape for advanced prostate cancer.

  • by

  • March 31, 2026

  • 3 min
It's Like PCR, But Better

Geoff Smith introduces the mcPCR method for methylated DNA analysis that is expanding the potential of epigenetics for disease detection